Revolution Medicines to Participate in April 2025 Investor Conferences

Rhea-AI Summary

Revolution Medicines (RVMD), a late-stage clinical oncology company focused on developing targeted therapies for RAS-addicted cancers, has announced its participation in two major investor conferences in April 2025.

The company's CEO and chairman, Mark A. Goldsmith, M.D., Ph.D., will engage in fireside chats at the following events:

• Needham 24th Annual Virtual Healthcare Conference on Monday, April 7 at 2:15 p.m. ET
• Stifel 2025 Virtual Targeted Oncology Forum on Wednesday, April 9 at 1:00 p.m. ET

Live webcasts and replays of both events will be accessible through the company's investor relations website for a minimum of 14 days following the presentations.

REDWOOD CITY, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will participate in in two upcoming investor conferences.

Details of the company’s participation are as follows:

• Needham 24^th Annual Virtual Healthcare Conference
  • Fireside Chat: Monday, April 7 at 2:15 p.m. ET

• Stifel 2025 Virtual Targeted Oncology Forum
  • Fireside Chat: Wednesday, April 9 at 1:00 p.m. ET

To listen to a live webcast of any of these events, or access archived webcasts, please visit: https://ir.revmed.com/events-and-presentations. Following the live webcasts, replays will be available on the company’s website for at least 14 days.

About Revolution Medicines, Inc.
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are currently in clinical development. The company anticipates that RMC-5127, a RAS(ON) G12V-selective inhibitor, will be its next RAS(ON) inhibitor to enter clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit www.revmed.com and follow us on LinkedIn.

Revolution Medicines Media & Investor Contact:
media@revmed.com
investors@revmed.com

FAQ

When is Revolution Medicines (RVMD) presenting at the Needham Healthcare Conference in April 2025?

Revolution Medicines will present at the Needham Virtual Healthcare Conference on Monday, April 7, 2025, at 2:15 p.m. ET.

What investor conferences is RVMD attending in April 2025?

RVMD is participating in two conferences: the Needham 24th Annual Virtual Healthcare Conference and the Stifel 2025 Virtual Targeted Oncology Forum.

How long will RVMD's investor conference webcasts be available for replay?

The webcasts will be available for replay on the company's website for at least 14 days following the live events.

What type of cancer treatments is Revolution Medicines (RVMD) developing?

Revolution Medicines is developing targeted therapies specifically for patients with RAS-addicted cancers.

Where can investors access RVMD's April 2025 conference presentations?

Investors can access the live webcasts and replays through Revolution Medicines' investor relations website at ir.revmed.com/events-and-presentations.